{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:31:19Z","timestamp":1760646679988},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Australian-American Fulbright postdoctoral scholarship"},{"name":"National Health and Medical Research Council Fellowships"},{"DOI":"10.13039\/501100003921","name":"Australian Government Department of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","ijdp.org","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.drugpo.2017.06.007","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T15:00:43Z","timestamp":1500562843000},"page":"69-76","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Trends in hepatitis C antibody prevalence among Aboriginal and Torres Strait Islander people attending Australian Needle and Syringe Programs, 1996\u20132015"],"prefix":"10.1016","volume":"47","author":[{"given":"Simon","family":"Graham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Maher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Handan","family":"Wand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugpo.2017.06.007_bib0005","unstructured":"Australian Bureau of Statistics. (2016). Prisoners in Australia. Australian Bureau of Statistics. Retrieved 20 May 2017 from http:\/\/www.abs.gov.au\/ausstats\/abs@.nsf\/mf\/4517.0."},{"key":"10.1016\/j.drugpo.2017.06.007_bib0010","series-title":"The health and welfare of Australia\u2019s Aboriginal and Torres Strait Islander peoples","author":"Australian Institute of Health and Welfare","year":"2015"},{"issue":"5","key":"10.1016\/j.drugpo.2017.06.007_bib0015","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1465-3362.2010.00173.x","article-title":"Perceptions of discriminatory treatment by staff as predictors of drug treatment completion: Utility of a mixed methods approach","volume":"29","author":"Brener","year":"2010","journal-title":"Drug and Alcohol Review"},{"issue":"S1","key":"10.1016\/j.drugpo.2017.06.007_bib0020","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1111\/1753-6405.12402","article-title":"Experiences of diagnosis care and treatment among Aboriginal people living with hepatitis C","volume":"40","author":"Brener","year":"2016","journal-title":"Australian and New Zealand Journal of Public Health"},{"key":"10.1016\/j.drugpo.2017.06.007_bib0025","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/dar.12320","article-title":"Illicit and injecting drug use among Indigenous young people in urban, regional and remote Australia","volume":"35","author":"Bryant","year":"2016","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/j.drugpo.2017.06.007_bib0030","series-title":"National Prison Entrants\u2019 Bloodborne Virus Survey","author":"Butler","year":"2015"},{"issue":"6","key":"10.1016\/j.drugpo.2017.06.007_bib0035","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S1470-2045(08)70150-5","article-title":"Incidence, aetiology, and outcomes of cancer in Indigenous peoples in Australia","volume":"9","author":"Cunningham","year":"2008","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.drugpo.2017.06.007_bib0040","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0376-8716(98)00028-3","article-title":"Self-report among injecting drug users: A review","volume":"51","author":"Darke","year":"1998","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.drugpo.2017.06.007_bib0045","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2893.2007.00942.x","article-title":"Risk of hepatitis C virus transmission through drug preparation equipment: A systematic and methodological review","volume":"15","author":"De","year":"2008","journal-title":"Journal of Viral Hepatitis"},{"issue":"4","key":"10.1016\/j.drugpo.2017.06.007_bib0050","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jcv.2014.01.014","article-title":"Comparison of hepatitis C virus RNA and antibody detection in dried blood spots and plasma specimens","volume":"59","author":"Dokubo","year":"2014","journal-title":"Journal of Clinical Virology"},{"issue":"10","key":"10.1016\/j.drugpo.2017.06.007_bib0055","first-page":"629","article-title":"The changing therapeutic landscape for hepatitis C","volume":"196","author":"Dore","year":"2012","journal-title":"MJA"},{"issue":"1","key":"10.1016\/j.drugpo.2017.06.007_bib0060","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.drugalcdep.2007.09.008","article-title":"Barriers associated with the treatment of hepatitis C virus infection among illicit drug users","volume":"93","author":"Grebely","year":"2008","journal-title":"Drug and Alcohol Dependence"},{"issue":"7","key":"10.1016\/j.drugpo.2017.06.007_bib0065","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/cid\/cit377","article-title":"Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: Feasibility and future requirements","volume":"57","author":"Grebely","year":"2013","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1016\/j.drugpo.2017.06.007_bib0070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/hep.26639","article-title":"The effects of female sex, viral genotype, and IL28 B genotype on spontaneous clearance of acute hepatitis C virus infection","volume":"59","author":"Grebely","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.drugpo.2017.06.007_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugpo.2016.12.004","article-title":"High risk injecting behaviour among people who inject pharmaceutical opioids in Australia","volume":"42","author":"Iversen","year":"2017","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2017.06.007_bib0080","series-title":"Needle syringe program national minimum data collection: National data report.","first-page":"2016","author":"Iversen","year":"2017"},{"issue":"8","key":"10.1016\/j.drugpo.2017.06.007_bib0085","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.2105\/AJPH.2012.301206","article-title":"Reduction in HCV incidence among injection drug users attending Needle and Syringe Programs in Australia: A linkage study","volume":"103","author":"Iversen","year":"2013","journal-title":"American Journal of Public Health"},{"issue":"1\u20132","key":"10.1016\/j.drugpo.2017.06.007_bib0090","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.drugalcdep.2012.05.008","article-title":"High-risk drug-use practices among a large sample of Australian prisoners","volume":"126","author":"Kinner","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2017.06.007_bib0095","series-title":"Hepatitis B and C in Australia Annual Surveillance Report Supplement","author":"Kirby Institute","year":"2016"},{"key":"10.1016\/j.drugpo.2017.06.007_bib0100","first-page":"26","article-title":"Estimating the cost-effectiveness of needle-syringe programs in Australia","author":"Kwon","year":"2012","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.drugpo.2017.06.007_bib0105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5694\/j.1326-5377.1997.tb140102.x","article-title":"HIV prevalence and risk behaviour in needle exchange attenders: a national study. The Collaboration of Australian Needle Exchanges","volume":"166","author":"MacDonald","year":"1997","journal-title":"Medical Journal of Australia"},{"issue":"1","key":"10.1016\/j.drugpo.2017.06.007_bib0110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1753-6405.2007.00007.x","article-title":"High hepatitis C incidence in new injecting drug users: A policy failure?","volume":"31","author":"Maher","year":"2007","journal-title":"Australian and New Zealand Journal of Public Health"},{"issue":"9791","key":"10.1016\/j.drugpo.2017.06.007_bib0115","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews","volume":"378","author":"Nelson","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.drugpo.2017.06.007_bib0120","series-title":"Summary of key findings from the A-Track pilot survey (2011\u20132012)","author":"Public Health Agency of Canada","year":"2013"},{"issue":"Suppl. 2","key":"10.1016\/j.drugpo.2017.06.007_bib0125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1478-3231.2011.02540.x","article-title":"A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt","volume":"31","author":"Sievert","year":"2011","journal-title":"Liver International"},{"issue":"632","key":"10.1016\/j.drugpo.2017.06.007_bib0130","article-title":"The Cedar Project: High incidence of HCV infections in a longitudinal study of young Aboriginal people who use drugs in two Canadian cities","volume":"12","author":"Spittal","year":"2012","journal-title":"BMC Public Health"},{"issue":"5","key":"10.1016\/j.drugpo.2017.06.007_bib0135","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/QAI.0b013e31816a1d68","article-title":"Representativeness of injecting drug users who participate in HIV surveillance: results from Australia's Needle and Syringe Program Survey","volume":"47","author":"Topp","year":"2008","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"5","key":"10.1016\/j.drugpo.2017.06.007_bib0140","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1753-6405.2011.00743.x","article-title":"Higher HCV antibody prevalence among indigenous clients of needle and syringe programs","volume":"35","author":"Ward","year":"2011","journal-title":"Australian and New Zealand Journal of Public Health"},{"issue":"229","key":"10.1016\/j.drugpo.2017.06.007_bib0145","article-title":"Demographic, risk behaviour and personal network variables associated with prevalent hepatitis C, hepatitis B, and HIV infection in injection drug users in Winnipeg, Canada","volume":"13","author":"Wylie","year":"2006","journal-title":"BMC Public Health"}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395917301780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395917301780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T04:29:08Z","timestamp":1569904148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395917301780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":29,"alternative-id":["S0955395917301780"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2017.06.007","relation":{},"ISSN":["0955-3959"],"issn-type":[{"value":"0955-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in hepatitis C antibody prevalence among Aboriginal and Torres Strait Islander people attending Australian Needle and Syringe Programs, 1996\u20132015","name":"articletitle","label":"Article Title"},{"value":"International Journal of Drug Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugpo.2017.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}